

# Eli Lilly & Co

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.


## STOCK DESCRIPTION:

Company Name:	Eli Lilly & Co	Market Capitalization (billion):	89.59
Ticker:	LLY US	Estimated EPS:	1.04
Currency:	USD	Estimated P/E:	19.39
ISIN:	US5324571083	Current P/E:	25.62
Last Price:	81.20	Next earnings release date:	2017-07-25
Target Price*:	88.55	Indicated Dividend Yield:	2.56%
Investment Rating*:	Buy	Return on Equity:	19.16%

\*Source: Bloomberg consensus

## LATEST NEWS:

- Eli Lilly published first quarter financial results that were slightly ahead of expectations as its experimental drug succeeded in late-stage clinical trials. The company posted adjusted earnings of 98 cents per share, while analysts expected no more than 96 cents per share.
- Eli Lilly said it would seek regulatory approval of its experimental breast cancer drug abemaciclib which proved to significantly increase patients' survival rates. Earlier this month, the company failed to secure the approval of another potential blockbuster drug baricitinib, which came as a surprise to investors.
- Shares in Eli Lilly fell 2.82% on Tuesday. US markets closed higher, absorbing gains in Materials, Energy, and Financials.



# Coca-Cola Co

The Coca-Cola Co manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.


## STOCK DESCRIPTION:

Company Name:	Coca-Cola Co	Market Capitalization (billion):	185.03
Ticker:	KO US	Estimated EPS:	0.58
Currency:	USD	Estimated P/E:	22.83
ISIN:	US1912161007	Current P/E:	22.76
Last Price:	43.11	Next earnings release date:	2017-07-26
Target Price*:	44.95	Indicated Dividend Yield:	3.43%
Investment Rating*:	Buy	Return on Equity:	26.06%

\*Source: Bloomberg consensus

## LATEST NEWS:

- Sales in Coca-Cola fell as much as 11% in the first quarter amid a major restructuring of the business. Revenues were down to \$9.1bn from about \$10.3bn a year ago. Earnings came at 23 cents a share and were below analysts' expectations.
- The company has been overhauling its business, attempting to achieve up to \$3bn in annual savings by 2019. Coca-Cola is targeting a more health conscious consumer and is selling off parts of its bottling business to diversify away from soft drinks.
- Shares in Coca-Cola dropped 0.35% on Tuesday.



# Credit Suisse AG

Credit Suisse Group AG is an international financial services group. The Group provides investment banking, private banking, and asset management services to customers located around the world.


## STOCK DESCRIPTION:

Company Name:	Credit Suisse AG	Market Capitalization (billion):	31.98
Ticker:	CSGN VX	Estimated EPS:	0.31
Currency:	CHF	Estimated P/E:	16.81
ISIN:	CH0012138530	Current P/E:	-
Last Price:	15.30	Next earnings release date:	2017-04-26
Target Price*:	15.34	Indicated Dividend Yield:	4.58%
Investment Rating*:	Hold	Return on Equity:	-6.29%

\*Source: Bloomberg consensus

## LATEST NEWS:

- Credit Suisse announced a \$4bn capital raising and postponed plans to sell its Swiss business, which came as a surprise to investors who expected limited news on the bank's capital structure. The rights issue will be offered to existing investors at a discount, while excess supply will be underwritten by Deutsche Bank and Morgan Stanley.
- Additional capital will allow Credit Suisse to invest in growth, strengthen the balance sheet, and cover the costs associated with the restructuring. The bank beat analysts' expectations in the first quarter by delivering a CHF 670m in pre-tax profits against the forecast of CHF 648m.
- Shares in Credit Suisse rose 1.66% on Tuesday.



## Authors



**Andrejs Kočetkovs**  
Head of the Investment Sales  
and Advisory Division



**Maksim Naruta**  
Investment Analyst

## CONTACT US

### Legal address and details:

**Baltikums Bank AS**

Office: Maza Pils iela 13,  
Rīga, LV-1050, Latvia  
[info@blueorangebank.com](mailto:info@blueorangebank.com)

### Investment Sales & Advisory Department:

Phone: +371 67 034 202  
[investment@blueorangebank.com](mailto:investment@blueorangebank.com)

[www.blueorangebank.com](http://www.blueorangebank.com)

## Important Legal Information

### No Offer

Nothing contained herein constitutes an offer, solicitation or recommendation regarding any investment product or service, or the offer to sell or the solicitation of an offer to buy any financial instrument; nor shall any such services be provided, or financial instruments be offered or sold, in any jurisdiction in which such an offer, solicitation, provision or sale would be unlawful. All content is subject to applicable statutes and regulations. Any potential investor should satisfy oneself that an investment in any product and/or service mentioned in this material is permissible under the rules and regulations of his or her domicile. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the availability of the material is prohibited.

The information provided is for reference only and investors should determine for themselves whether a particular service or product is suitable and appropriate for their investment needs or should seek such professional advice for their particular situation. Please refer to offering documents for further information concerning specific products.

Certain statements contained herein may be statements of future expectations and other forward-looking statements that are based on current views and assumptions of BlueOrange (the trade name operated by the legal entity Baltikums Bank AS – hereinafter referred to as "BlueOrange") and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential, or continue" and similar expressions identify forward-looking statements. BlueOrange assumes no obligation to update any forward-looking information contained herein.

### Investments

Past performance is no guarantee of future results. Investing in the financial markets is subject to certain risks including market, interest-rate, issuer, credit, and inflation risk. Financial instruments may appreciate or depreciate in price owing to conditions, whether real or apparent, in a given market, economy or industry. The value of investments, and the income from them, can go down as well as up, and you may not recover the amount of your original investment. Where investments involve currency exposure, changes in rates of exchange may cause the value of the investment to go up or down. Any tax benefits referred to on this material are subject to change and their availability and value will depend on your individual circumstance.

### No Reliance

Although BlueOrange has taken reasonable care to ensure that the information contained within this material is accurate, no representation or warranty (including liability towards third parties), expressed or implied, is made as to its accuracy, reliability or completeness by BlueOrange. Opinions and any other contents of the material are provided by BlueOrange for personal use and for tentative reference only. Nothing contained on this material constitutes investment, legal, tax or other advice and is not to be relied on in making an investment or other decision.